A Single Variant That Delays the Inevitable

Inside the Yamamoto lab's arc from a Venezuelan pedigree to a shared therapeutic target across Huntington's, Parkinson's, and tauopathies, and the point mutation knockin that recapitulated 23 years of protection in a mouse.

Huntington's disease is one of the most mechanistically well defined neurodegenerative disorders in medicine. The CAG repeat expansion in HTT is the cause. The age at which symptoms appear, however, varies significantly across patients with similar repeat lengths. Something else is going on.

Working from a Venezuelan pedigree, the Yamamoto lab at Columbia, with collaborators at MIT, Stanford, UCLA, the University of Oslo, and the New York Genome Center, identified a rare single nucleotide polymorphism in WDFY3 associated with an onset delay of up to 23 years in carriers.

The next question was whether the variant itself was causal, or merely correlated with protection. Answering that required moving from human genetics to a mouse model with the exact variant introduced at the orthologous position.

The model

Ingenious Targeting Laboratory generated the point mutation knockin introducing the orthologous SNP into the endogenous mouse Wdfy3 locus. The team also built a Rosa26 cDNA knockin overexpressing human ALFY, the protein encoded by WDFY3. Both models were generated on a C57BL/6 background.

The point mutation strategy was the critical piece. A transgenic would have introduced the variant at a random locus with variable expression; a straight knockout would have told them nothing about the SNP specifically. The knockin preserved endogenous regulation and made the resulting phenotype directly attributable to the variant.

The result

Both models recapitulated the human phenotype. Mice carrying the variant showed delayed neuropathological and behavioral dysfunction in two independent Huntington's models (Q140 and N171-82Q). Ectopic overexpression of hALFY from the Rosa26 locus produced the same neuroprotective effect, which was the mechanistic proof that elevated ALFY expression was the operative change.

Then the study expanded. The same Alfy elevation protected against phospho-α-synuclein accumulation in a Parkinson's PFF model and AT8-positive tau pathology in the PS19 tauopathy model. What started as a Huntington's modifier ended as a candidate therapeutic target across multiple proteinopathies.

Why it matters

Huntington's, Parkinson's, and Alzheimer's have historically been studied as separate diseases. This work, grounded in a natural human variant and validated in mouse models that preserved endogenous regulation, identified a single pathway whose augmentation provides protection across all three. The translational implication is significant: one therapeutic target, multiple disease contexts.